



**GMMM** Interface Prescribing  
Subgroup



**Agenda**

**9<sup>th</sup> April 2015, 1pm-3pm**

**HMR CCG**

**Room 410, Number One Riverside, Smith St. Rochdale OL16 1XU**

[Declarations of Interest](#) (new declarations only)

Apologies:

	<b>ENC</b>
<b>1) Draft Minutes of 12<sup>th</sup> March 2015</b>	Item 1
<b>2) Matters Arising</b> <ul style="list-style-type: none"> <li>a) RAG List Recommendations LMWH – awaiting GMMM approval</li> <li>b) RAG List Recommendations from January meeting – now GMMM approved</li> <li>c) RAG List Recommendations from February meeting – awaiting GMMM approval</li> <li>d) RAG List Recommendations from March meeting (Drugs for alcohol dependence, Chapter 3 and 13) – comments due by 7<sup>th</sup> May</li> <li>e) Antidementia drugs leaflets –now GMMM approved</li> <li>f) Chapter 10 SCP Protocol Review – on hold</li> <li>g) Chapter 9 SCP Review - hydroxycarbamide</li> <li>h) Chapter 5 SCP Review - colistimethate for non-CF patients</li> <li>i) Chapter 4 SCP Review – ADHD Drugs</li> <li>j) Chapter 6 SCP Review – Denosumab - comments due by 7th May</li> </ul>	Item 2g Item 2j
<b>3) Chapter 1 RAG list review – drugs for review</b> <ul style="list-style-type: none"> <li>a) Colesevelam – currently Green (following specialist advice)</li> <li>b) Linaclotide – currently Green (following specialist initiation)</li> <li>c) Mercaptopurine – currently Amber</li> <li>d) Methotrexate (oral) – currently Amber</li> <li>e) Metoject(R) – no status</li> <li>f) Sulfasalazine – currently Amber</li> <li>g) Mesalazine – no status (Green following specialist initiation on formulary)</li> </ul>	Item 3

- h) Prednisolone enema - no status (Green following specialist initiation on formulary)
- i) Prednisolone foam - no status (Green following specialist initiation on formulary)
- j) Prednisolone suppositories - no status (Green following specialist initiation on formulary)
- k) Prucalopride - no status (Green following specialist initiation on formulary)
- l) Colestyramine - no status (Green following specialist initiation on formulary)
- m) Pancreatin (Creon® - no status (Green following specialist initiation on formulary)

#### 4) Chapter 1 Shared Care Protocol review – existing guidelines

Document Title	BNF	Organisation	Date	Review date	In GMMMG Format
<a href="#">Azathioprine and 6-Mercaptopurine for Chronic Inflammatory Bowel Disease</a>	1	Pennine Acute	Aug 2012	Aug-14	Yes
<a href="#">Azathioprine or 6 Mercaptopurine for the treatment of chronic inflammatory bowel disease</a>	1	CMFT	Jul 2013	Jul-15	Yes

#### 5) Chapter 1 Shared Care Protocol review – drugs without an SCP Sulfasalazine

#### 6) Chapter 8 RAG list review – drugs for review

- a) Chemotherapy Drugs – currently Red
- b) Abiraterone – currently Red
- c) Anastrozole – currently Green (following specialist initiation)
- d) Azathioprine – currently Amber (no SCP in place)
- e) Interferon beta – currently Red
- f) Bicalutamide – currently Amber and Green (following specialist initiation) on list
- g) Ciclosporin – currently Amber (no SCP in place)
- h) Degarelix – currently Red
- i) Exemestane – currently Green (following specialist initiation)
- j) Flutamide – currently Amber (no SCP in place, not in formulary)
- k) Fulvestrant – currently Amber for pts pre Dec 2011 and Red for patients post Dec 2011
- l) Histrelin – currently Amber (no SCP in place, not in formulary)
- m) Hydroxycarbamide (thrombocythaemia or polycythaemia) – currently Amber (no SCP in place)
- n) Interferon alfa 2a & 2b – currently Red
- o) Lanreotide – currently Amber (no SCP in place)
- p) Letrozole – currently Green (following specialist initiation)

Item 6

- q) Mycophenolate – currently Amber (no SCP in place)
- r) Octreotide – currently Amber (no SCP in place)
- s) Sirolimus – currently Amber (no SCP in place)
- t) Basiliximab – no status (Red on formulary)
- u) Ofatumumab – no status (Red on formulary)
- v) Interferon gamma-1b – no status
- w) Canakinumab – no status (Red on formulary)
- x) Glatiramer acetate – no status (Red on formulary)
- y) Mifamurtide – no status (Red on formulary)
- z) Natalizumab – no status (Red on formulary)
- aa) Anti-thymocyte immunoglobulin – no status
- bb) Aprepitant – no status
- cc) Amiofostine – no status
- dd) Betacept – no status
- ee) Palifermin – no status

#### 7) Chapter 8 Shared Care Protocol review – existing guidelines

Document Title	BNF	Organisation	Date	Review date	In GMMG Format
<a href="#">Fulvestrant (Faslodex®) Injection</a>	8	The Christie	Apr 2010	Apr-12	No
<a href="#">Goserelin in the Treatment of Breast Cancer</a>	8	The Christie	Apr 2010	Apr-12	No
<a href="#">LEUPRORELIN (PROSTAP) for the treatment of endometriosis, endometrial thinning prior to surgery and reduction of uterine fibroids</a>	8	Pennine Acute	Nov 2011	Nov-14	Yes
<a href="#">Bicalutamide</a>	8	Tameside and Glossop	Feb 2012	?	No

#### 8) Chapter 8 Shared Care Protocol review – drugs without an SCP

- Hydroxycarbamide – essential thrombocythaemia or polycythaemia
- Lanreotide
- Mycophenolate (transplant indications)
- Octreotide
- Sirolimus
- Tacrolimus
- Flutamide
- Histrelin

#### 9) Strontium – review of RAG status

Item 9

#### 10) Lanthanum – review of RAG status

#### 11) Trientine – review of RAG status

<b>12) Ethinylestradiol for pubertal induction</b>	Item 12
<b>13) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</b> <ul style="list-style-type: none"> <li>a) DuoResp® (Budesonide/formoterol) inhaler</li> <li>b) Tapentadol – not for routine prescribing &amp; FSG added to Grey list.</li> <li>c) Relvar® inhaler</li> <li>d) Nabilone for the treatment of chronic non cancer pain (unlicensed indication)</li> <li>e) Acridinium/Formoterol (Duaklir® Genuair® ▼) 340/12 combination inhaler</li> </ul>	
<b>14) Draft Shared Care Protocols for Discussion</b> <ul style="list-style-type: none"> <li>• Ciclosporin for use in childhood nephrotic syndrome</li> </ul>	Item 14
<b>15) Shared Care Protocols for Approval</b> <ul style="list-style-type: none"> <li>• Cinacalcet primary hyperparathyroidism</li> <li>• Ibandronate for breast cancer - comments due by 7th May</li> </ul>	Item 15i Item 15ii
<b>16) Forward work plan</b>	Item 16
<b>17) Updates from other groups</b>	
a) Formulary Subgroup (verbal)	
b) New Therapies Subgroup (verbal)	
c) GMMMG (verbal)	
<b>18) AOB</b>	
<b>Date of Next Meeting: 14<sup>th</sup> May 2015, 1pm-3pm Room 410, HMR CCG, Number One Riverside, Smith St, Rochdale OL16 1XU</b>	